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Introduction: Initiation of peritoneal dialysis (PD) with 3 exchanges has become common
practice in recent years, despite the lack of published clinical data.
Objective: To describe experience with incremental peritoneal dialysis (IPD) at a single site.
Material and methods: A total of 46 IPD patients undergoing 2-year clinical, laboratory, treat-
ment and progression follow-up.
Results: To 25% of patients were transplanted on IPD. Mean time on IPD before transfer to
conventional PD of 24 months, half of the patients because of ﬂuid balance. Good clinical
and biochemical results with a peritonitis rate of one episode per 99 months. There was an
improvement in the loss of residual kidney function compared to the pre-dialysis period
(−7.06  vs. −1.58 ml/min/year; P = .0001).
Conclusions: IPD with 3 peritoneal exchanges offers good results. Most patients remain stable
during the ﬁrst 2 years and there is an improvement in the loss of residual kidney function
compared to the pre-dialysis period.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Diálisis  peritoneal  incremental:  resultados  clínicos  y  preservación  de  la
función  renal  residual
r  e  s  u  m  e  nalabras clave:
iálisis peritoneal incremental
unción renal residual
nicio de diálisis
Introducción: En los últimos an˜os el inicio de diálisis peritoneal (DP) con 3 recambios se
ha  convertido en una práctica habitual, aunque se dispone de pocos resultados clínicos
publicados.
Objetivo: Descripción de la experiencia de inicio con DP incremental (DPI) en un centro.
 Please cite this article as: Borràs Sans M, Chacón Camacho A, Cerdá Vilaplana C, Usón Nun˜o A, Fernández E. Diálisis peritoneal
ncremental: resultados clínicos y preservación de la función renal residual. Actas Urol Esp. 2016;36:299–303.
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300  n e f r o l o g i a. 2 0 1 6;3 6(3):299–303
Material y métodos: A 46 pacientes en DPI se les realizó seguimiento clínico, analítico y
tratamiento, y se estudió su evolución a 2 an˜os.
Resultados: A un 25% de los pacientes se les trasplanta en DPI. Tiempo medio de trans-
ferencia a DP convencional de 24 meses. La mitad de los pacientes son transferidos por
manejo de líquidos. Buena estabilidad clínica y analítica con tasa de peritonitis de un episo-
dio  cada 99 meses. Enlentecimiento de la pérdida de función renal residual respecto al
período prediálisis (−7,06 vs. −1,58 ml/min/an˜o; p = 0,0001).
Conclusiones: La experiencia en DPI con 3 recambios de inicio es positiva. La mayoría de los
pacientes se mantienen estables durante los 2 primeros an˜os, con un enlentecimiento de
la  pérdida de función renal residual respecto el período prediálisis.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
In recent years it has been proposed to start peritoneal dialy-
sis (PD) using the modality of incremental peritoneal dialysis
(IPD). This is deﬁned as starting PD with 3 or fewer periton-
eal exchanges per day. The IPD modality is postulated as an
option for patients who  start dialysis before manifestations of
severe uraemia are present.1,2
By performing fewer exchanges per day, patients on IPD
would have a reduced risk of peritonitis and a better quality
of life. Furthermore, by reducing peritoneal glucose exposure
and absorption, the peritoneal membrane should be better
preserved, with less chronic inﬂammation and alterations in
carbohydrate metabolism. All this would contribute to pre-
serve future vascular accesses,3–5 in case there is a need to
switch to haemodialysis (HD). It has also been reported that
acceptable levels of solute clearance are maintained in IPD and
there is an adequate control of other biochemical parameters,
while residual renal function (RRF) is preserved. It should be
highlighted that one study shows that in IPD there is slowing-
down in the rate of renal function loss as compared to that
observed during the pre-dialysis period.6
Another study compares the evolution of patients who
received transplantation during the ﬁrst 3 years on dialysis.
As compared with HD patients, IPD patients have a lower inci-
dence of delayed graft function and better long-term clinical
results, both for the patient and the graft.7
Lastly, the possibility of starting treatment with IPD
encourages patients to choose the modality of PD more
often, particularly continuous ambulatory peritoneal dialysis
(CAPD).6
The increased number of patients starting a pre-scheduled
renal replacement therapy (RRT) and the potential advantages
of IPD have led many  PD centres to choose this modality in
recent years. Nevertheless, there is limited evidence on the
beneﬁts and on the clinical management of these patients.
Few studies analysing IPD are available and most of them are
retrospective with short number of patients, no control group
and carried out in the same country, which means the results
cannot be extrapolated to other populations on dialysis.Therefore, the objective of this study is to analyse the clin-
ical and analytical characteristics of patients during the 2 ﬁrst
years on IPD, as well as patients prognosis and outcomes.by-nc-nd/4.0/).
Material  and  methods
Design: descriptive, longitudinal and retrospective study.
Patients
We included all patients from the Lleida Hospital Arnau de
Vilanova PD unit who started CAPD using IPD, that is, 3 or
fewer exchanges per day. We excluded patients who  started
CAPD using conventional treatment (4 exchanges) or those on
automated peritoneal dialysis (APD).
Data
The study period started in August 2003 (date when the ﬁrst
IPD patient was included in the study) and ended in December
2012 (ﬁnal data collection date).
The data collected included variables on demographics,
anthropometric and analytical data and dialysis and phar-
macological treatment data (number of antihypertensives,
number of phosphate chelating agents, use of ACE inhibitors
or ARBs, diuretics, paricalcitol and cinacalcet and darbepo-
etin doses). Comorbidity was estimated using the Charlson
index evaluated for PD unadjusted by age.8 Adequacy was cal-
culated using Kt/V (renal, peritoneal and total) and RRF using
combined 24 h urinary urea and creatinine clearances. These
data were collected at the start of IPD, and at 6, 12, 18 and 24
months of IPD treatment. In the case of RRF, progression was
also recorded in the last predialysis year for stable patients
with a minimum of 4 valid determinations. Peritoneal func-
tion was estimated using the peritoneal equilibration test at
the start of the modality and it was repeated each year. The
rate of peritonitis was also calculated for the ﬁrst 2 years on
IPD.
Regarding the evolution on this modality, we  recorded
time on PD, on IPD and reasons for suspension of IPD, renal
transplant, deaths, switching to HD, clinical manifestations of
uraemia, Kt/V < 2 without clinical manifestations of uraemia,
ﬂuid overload and switching to APD due to patient’s choice.
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tatistics
he Kolmogorov–Smirnov test was used to determine normal
istribution of continuous variables. We expressed quanti-
ative variables as means with standard deviation. Bivariate
omparisons were performed using the Student’s t-test for
aired samples. Comparisons between qualitative variables,
xpressed as frequency or percentage, were performed with
he test 2. Results were considered to be signiﬁcant with a
-value <0.05 (95% conﬁdence interval).
esults
uring the study period, 75 patients were included in the PD
rogramme; of these, 28 patients were excluded for choosing
PD and one patient for starting the conventional modal-
ty due to a medical history of severe heart disease. A total
f 46 patients started the IPD, of whom 39 (84.8%) came
rom the multidisciplinary advanced kidney disease clinics
MAKDC), 4 (8.7%) came from hemodialysis HD and 3 (6.5%)
ad renal transplant with poor renal function. Table 1 shows
he baseline characteristics of the patients (epidemiological,
nthropometric, RRF and pharmacological treatment).
All patients started IPD treatment with 3 exchanges per
ay, at a volume ranging from 1500 to 2000 ml  per exchange.
he treatment always included an icodextrin exchange
Extraneal®) and in 18 (39.1%) of the patients an amino acid
Table 1 – Clinical data and baseline treatment.
n = 46
Age (years) 62.0 (17.3)
Men (%) 65.2
Smokers or ex (%) 37.0
Diabetics (%) 30.4
BMI (kg/m2) 25.9 (4.2)
Primary kidney disease n (%)
Vascular 26.1
Diabetic 23.9
Interstitial 17.4
Glomerular 15.2
Unknown 10.9
Polycystic kidney disease 4.3
Other 2.2
Treatments
ACE inhibitors and/or ARBs n (%) 21 (45.7)
Diuretics n (%) 32 (69.6)
Paricalcitol (%) 39.5
Cinacalcet (%) 2.3
Number of antihypertensives 2.4 (1.2)
Number of phosphorus-chelating agents 0.6
Darbepoetin (g/kg/week) 0.4 (0.5)
Charlson index 3.4 (1.6)
SBP (mmHg) 138 (20)
DBP (mmHg) 72 (12)
Glomerular ﬁltration rate, ml/min/1.73 m2 8.0 (3.2)
Diuresis volume, ml/24 h 1367 (598)
Values expressed as percentages or mean and (standard deviation).
SBP, systolic blood pressure; DBP, diastolic blood pressure;
ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs,
angiotensin II receptor blockers.(3):299–303 301
exchange (Nutrineal®). The other exchanges were with the
dialysis solution Physioneal® at a glucose concentration of
1.36%.
The mean time on IPD was 22.5 ± 14 months (range: 6–61).
During follow-up, 11 (24%) patients received transplantation
while they were on IPD, 3 patients were switched to HD (2 due
to severe peritonitis and one due to an unresolved alteration
in the abdominal wall), 2 patients died (due to terminal multi-
ple myeloma and disseminated cancer with pneumonia) and
22 (47.8%) of the patients were switched to conventional PD.
The mean time on IPD in the subgroup of patients switched
to conventional PD was 24.5 months. The reasons for the
switch to conventional PD were: ﬂuid overload in 9 (40.9%)
patients; Kt/V < 2 without clinical manifestations of uraemia
in 7 (31.8%) patients; clinical manifestations of uraemia in 5
(22.7%) patients; and preference of APD in one patient. At the
end of the study period, 8 (36.36%) patients continued on IPD.
Table 2 shows the progression of RRF, adequacy and perit-
oneal function parameters in the ﬁrst 2 years of IPD follow-up.
During this period there was a decrease in glomerular ﬁltra-
tion rate (GFR) of around 1.5 ml/min/year, accompanied by a
decrease in renal Kt/V. Total ﬂuid loss also decreased due to a
reduction of diuresis. Comparison of the annual loss of renal
function during pre-dialysis period with the ﬁrst 2 years of IPD
showed that the rate of renal function deterioration slowed
down when patients started PD: −7.06 ml/min/year before ini-
tiation of IPD vs. −1.58 ml/min/year in IPD; p = 0.0001. None
of the patients who started IPD experienced anuria during the
follow-up period. Regarding peritoneal function, an increase in
solute transport was observed (D/P cr), which was signiﬁcant
in the second year, with no loss of UF capacity.
Table 3 shows the outcome of clinical, analytical and
pharmacological parameters. The mean weight increased
non-signiﬁcantly; blood pressure (BP) did not change except
for the diastolic BP that was decreased at 2 years. There
were no signiﬁcant changes in the number of antihypertensive
drugs prescribed. Regarding mineral metabolism parameters,
the serum calcium and phosphorus levels were stable with
a tendency for intact parathormone levels to decrease. This
was controlled through a signiﬁcant increase in phosphorus
chelating agents from baseline and an increase in the number
of patients on treatment with paricalcitol and cinacalcet. Fig. 1
shows the progression of haemoglobin levels and darbepoetin
dose. Haemoglobin levels remained stable, within acceptable
ranges. It should be highlighted that these levels were main-
tained in spite of a signiﬁcant reduction of darbepoetin doses
prescribed throughout the follow-up period.
Lastly, of the population studied, 10 (21.7%) patients pre-
sented an episode of peritonitis during the ﬁrst 2 years on
IPD. The rate of peritonitis was one episode every 99 months,
which is comparable to the rate presented by the rest of the
population on PD in our unit during the same period.
DiscussionThis study shows that most patients starting IPD present con-
siderable clinical and analytical stability during the ﬁrst 2
years on this modality. Moreover, the loss of RRF slows down
compared to the year prior to starting PD.
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Table 2 – RRF progression, adequacy and PET.
Baseline
(n = 46)
6  months
(n = 46)
12  months
(n = 36)
18 months
(n  = 26)
24  months
(n  = 24)
GFR (ml/min/1.73 m2) 8.0  (3.2) 7.3 (2.9)* 6.9 (3.2)** 6.5 (3.0)** 5.7 (3.1)**
Diuresis volume (ml) 1366 (598) 1324 (595) 1229 (611) 1210 (454)** 1121 (409)**
Total UF (ml) 2305 (775) 2256 (701) 2215 (603) 2157 (580)* 2118 (523)**
Renal Kt/V 1.4 (0.6) 1.3 (0.5) 1.2 (0.6)* 1.2 (0.5)* 1.1 (0.6)**
Peritoneal Kt/V 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.4) 1.2 (0.3)
D/P cr 0.66 – 0.66 – 0.68*
PET UF Vol 2502 (334) – 2569 (206) – 2608 (226)
Compared to baseline value:
∗ p < 0.05.
∗∗ p < 0.001.
Values expressed as the mean and (standard deviation).
RRF, residual renal function; PET, peritoneal equilibration test.
Table 3 – Outcome of clinical, analytical and pharmacological parameters.
Baseline
n = 46
6 months
n  = 45
12  months
n  = 36
18 months
n  = 26
24 months
n  = 24
Weight (kg) 67.2 (1.7) 67.9 (11.6) 70.7 (11.3) 70.6 (10.8) 70.4 (10.6)
SBP (mmHg) 138 (19.6) 134 (21.7) 134 (19.9) 135 (23.4) 130 (22.6)
DBP (mmHg) 72 (11.7) 69 (10.7) 71 (11.6) 66 (7.9)*
No. of antihypertensives 2.4 (1.2) 2.3 (1.2) 2.4 (1.2) 2.4 (1.3) 2.3 (1.5)
Calcium (mmol/l) 2.19 (0.17) 2.19 (0.02) 2.22 (0.02) 2.24 (0.02) 2.24 (0.02)
Phosphorus (mmol/l) 1.42 (0.22) 1.35 (0.03) 1.42 (0.03) 1.43 (0.03) 1.42 (0.06)
PTH (pg/ml) 322 (170.9) 290 (20.7) 260 (20.5) 223 (10.3)* 240 (20)
No. of phosphorus-chelating agents 0.64 (0.61) 1 (0.78)** 1.12 (0.79)** 1.25 (0.73)** 1.12 ((0.78)*
Paricalcitol n (%) 17  (39) 26 (60.5) 28 (70) 29 (81) 28 (85)
Cinacalcet n (%) 1 (2.3) 5 (12) 7 (17) 5 (14)* 3 (9)
Compared to baseline value:
∗ p < 0.05.∗∗ p < 0.001.
Values expressed as the mean and (standard deviation).
The deﬁnition of IPD in CAPD has not been clearly estab-
lished. In most studies, IPD is deﬁned as patient on PD with 2
or fewer manual exchanges1,9. However, in other studies,6,10,11the incremental modality includes patients with 3 or fewer
exchanges prescribed according to glomerular ﬁltration rate
or Kt/V. We  chose a deﬁnition for IPD as starting PD with 3 or
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Fig. 1 – Progression of Hb levels and darbepoetin dose.fewer exchanges because the classic and standard description
of CAPD is 4 peritoneal exchanges,12 and this framework has
been used for several decades. In recent years, many  PD units
have adopted 3 or fewer peritoneal exchanges when the clini-
cal condition allows as the standard initial modality. Two facts
have contributed to this change: the decrease in adequacy
objectives13,14 and a greater number of patients with planned
dialysis start thanks to MAKDC. Although it is a routine clinical
practice, there is limited published data.
Our experience was largely positive. Firstly, because it
shows that many  patients starting PD can do it on IPD. Only in
one case starting with only 3 exchanges was contraindicated
due to, severe heart failure with several episodes of overhy-
dration. Patients not included on IPD were those that chose
APD as their starting modality. Nevertheless, there was a bias
in the choice for APD because it was the modality of choice
in a considerable number of patients who required a caregiver
or who had been referred from HD or renal transplant. We  do
not have data on starting APD using an incremental modality,
deﬁned in general as fewer than 6 days of weekly treatment.
Secondly, our experience was positive because during their
time on IPD, the patients remained clinically and analytically
stable, with low peritonitis rates and did not require increases
in prescribed medication. In fact, haemoglobin remained sta-
ble while darbepoetin doses had signiﬁcantly been reduced.
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alues of BP remained within normal ranges without the
eed to increase antihypertensive treatment; thus, the non-
igniﬁcant increase in weight should not be attributed to
verhydration. Lastly, serum calcium and phosphate con-
entration were maintained throughout follow-up, with a
ecrease in parathormone levels. In this case there was an
ncrease in the number of patients on phosphate-chelating
gents and treated with paricalcitol and cinacalcet. Notwith-
tanding, no patients had to be switched to standard CAPD or
D due to poor control of mineral metabolism.
A third aspect to be highlighted is the progression of RRF.
ean glomerular ﬁltration rate (GFR) at the before initiation of
PD was 8 ml/min. It should be noted that during the length of
he study the recommendation of relatively RRT start was fol-
owed, as indicated by guidelines. Currently, after the results
rom the IDEAL study15 and other publications, the indication
as to reconsider an early initiation of replacement therapy.
onetheless, it should be remembered that in the IDEAL study,
he mean GFR for the late start group was 9.2 ml/ml, although
t was calculated by estimating the creatinine clearance for-
ula corrected for body surface. In any case, our patients
id not start RRT with very high GFRs and, in any case, the
oss of RRF slowed down from −7.06 to −1.58 ml/min/year.
his is surely key to explaining IPD patient stability during
he 24 months that they remained on this modality. Viglino
t al.6 also observed a reduction in the rate of renal function
oss of 2.4 ml/min/year with IPD compared to the predialysis
eriod. This reduction in the loss of RRF cannot be attributed to
he incremental modality, given that Berlanga et al.16 already
eported this same effect with PD in general. However, it is
mportant to demonstrate that the incremental modality also
as this effect, given that the importance of preserving RRF in
D is beyond the clinical management; it is well known that
his factor is also associated to lower morbidity and mortality
n PD patients.17
Lastly, it is worth noting that one quarter of patients
eceived transplant while they were still on the incremental
odality. Patients who switched to the conventional modal-
ty were maintained on IPD for an average of 2 years in good
onditions, and ﬂuid management was the main reason for
witching to conventional PD. However, overhydration was
ot severe and there were no cases requiring hospitalization.
hirty-two per cent (32%) of patients were switched to con-
entional PD due to a Kt/V < 2, although they were entirely
symptomatic. This consideration should probably be recon-
idered in light of the most recent results and publications;
ome of these patients could have been maintained on IPD
ithout complications. In any case, individualised, case-by-
ase assessment and acquired experience will be crucial to
ptimise IPD and suitably switch to conventional PD.
In summary, we  had a positive experience at our centre
y starting PD with 3 peritoneal exchanges. Most patients
emained stable for the ﬁrst 2 years and one quarter of them
eceived transplant while on this modality. Moreover, we  con-
rmed a slow-down of RRF compared to the predialysis period.
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